AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22215002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 20029243 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaltoprofen 80 mg
Number of subjects: 170
Study 20029243 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaltoprofen 160 mg
Number of subjects: 170
Study 20029243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 18700222 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg intravenous diamorphine
Number of subjects: 14
Study 18700222 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg subcutaneous hydromorphone
Number of subjects: 14
Study 18700222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 16251561 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane 2, 4, and 6 mL
Number of subjects: 30
Study 16251561 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 5 mL
Number of subjects: 30
Study 16251561 — intervention group
Group type: COMPARATOR
Intervention: Halothane 1 mL, Isoflurane 1.5 mL, Sevoflurane 2.7 mL
Number of subjects: 30
Study 12717749 — intervention group
Group type: EXPERIMENTAL
Intervention: Test didanosine formulation (200 mg)
Number of subjects: 24
Study 12717749 — intervention group
Group type: COMPARATOR
Intervention: Reference didanosine formulation (200 mg)
Number of subjects: 24
Study 11077516 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased use of nurses and other health care professionals in diabetes care
Number of subjects: 0
Study 11077516 — intervention group
Group type: EXPERIMENTAL
Intervention: Remuneration for an annual review of patients with diabetes
Number of subjects: 0
Study 11077516 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarification of the division of work between primary health care and hospital clinics
Number of subjects: 0
Study 8780566 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline alone (1:100,000)
Number of subjects: 140
Study 8780566 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline plus human thrombin (600-1000 IU)
Number of subjects: 140
Study 1594257 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA group (n = 29)
Number of subjects: 60
Study 1594257 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group (n = 31)
Number of subjects: 60
Study 1594257 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 6588482 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole alone
Number of subjects: 136
Study 6588482 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole + ampicillin
Number of subjects: 136
Study 6588482 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole + doxycycline
Number of subjects: 136
Study 30063475 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants told 'this hearing in noise test (HINT) you are about to do is really hard'
Number of subjects: 59
Study 30063475 — intervention group
Group type: COMPARATOR
Intervention: Participants told 'this HINT test is really easy'
Number of subjects: 59
Study 30063475 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants comparing 'my setting' to 'another participant'
Number of subjects: 59
Study 30063475 — intervention group
Group type: COMPARATOR
Intervention: Participants comparing 'my setting' to 'expert audiologist'
Number of subjects: 59
Study 29633656 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (group I)
Number of subjects: 86
Study 29633656 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (group II)
Number of subjects: 86
Study 25956588 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2) 50 to 200 mcg/day
Number of subjects: 0
Study 25956588 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 0
Study 25956588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23788517 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 mg Bacopa monnieri (BM)
Number of subjects: 17
Study 23788517 — intervention group
Group type: EXPERIMENTAL
Intervention: 640 mg Bacopa monnieri (BM)
Number of subjects: 17
Study 23788517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 22233155 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (1, 2 or 3 mg)
Number of subjects: 30
Study 21058193 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol (first quartile)
Number of subjects: 0
Study 21058193 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (first quartile)
Number of subjects: 0
Study 21058193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18272031 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib as maintenance therapy
Number of subjects: 0
Study 18272031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16222233 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed temporal patterning of stimuli
Number of subjects: 0
Study 16222233 — intervention group
Group type: COMPARATOR
Intervention: Random interleaving of stimuli
Number of subjects: 0
Study 11590081 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of tobacco exposure by 50% or more
Number of subjects: 1583
Study 11590081 — intervention group
Group type: COMPARATOR
Intervention: No change in tobacco exposure
Number of subjects: 1583
Study 11590081 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-trimester cigarette use
Number of subjects: 1583
Study 11590081 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine cotinine concentration
Number of subjects: 1583
Study 9237290 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1% amino acid dialysate (AAD)
Number of subjects: 18
Study 9237290 — intervention group
Group type: COMPARATOR
Intervention: Dextrose dialysis
Number of subjects: 18
Study 8355383 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital-initiated treatment (aspirin and alteplase)
Number of subjects: 360
Study 8355383 — intervention group
Group type: COMPARATOR
Intervention: Hospital-initiated treatment (aspirin and alteplase)
Number of subjects: 360
Study 8355383 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment initiated within 70 minutes of symptom onset (both prehospital and hospital)
Number of subjects: 360
Study 3657877 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi vaccine
Number of subjects: 6907
Study 3657877 — intervention group
Group type: COMPARATOR
Intervention: Pneumococcus vaccine (control)
Number of subjects: 6907
Study 2477300 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact endoscopic laser treatment
Number of subjects: 20
Study 2477300 — intervention group
Group type: COMPARATOR
Intervention: Noncontact endoscopic laser treatment
Number of subjects: 20
Study 2091 — intervention group
Group type: EXPERIMENTAL
Intervention: Anileridine
Number of subjects: 28
Study 2091 — intervention group
Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 28
Study 30941731 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month physiotherapist-supervised home-based physical exercise program (n = 150)
Number of subjects: 300
Study 30941731 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 150)
Number of subjects: 300
Study 30941731 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 300
Study 28841561 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic Configuration Networks (SCNs)
Number of subjects: 0
Study 28841561 — intervention group
Group type: EXPERIMENTAL
Intervention: SC algorithms for data regression and classification
Number of subjects: 0
Study 25770082 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin (inflammatory challenge)
Number of subjects: 115
Study 25770082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 23574590 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone (DRSP) with ethinyl-estradiol 20 μg (DRSP/EE20)
Number of subjects: 432178
Study 23574590 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone (DRSP) with ethinyl-estradiol 30 μg (DRSP/EE30)
Number of subjects: 432178
Study 23574590 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel (LNG)
Number of subjects: 432178
Study 23574590 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone (DRSP)
Number of subjects: 432178
Study 21651736 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand washing (HW)
Number of subjects: 442
Study 21651736 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand washing plus paper surgical face masks (HW + FM)
Number of subjects: 442
Study 21651736 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 442
Study 19451831 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month exercise-based cardiac rehabilitation program
Number of subjects: 0
Study 19451831 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 16397160 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted promotional tools developed based on audience segmentation
Number of subjects: 0
Study 14746594 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic scleral buckling with pars plana vitrectomy
Number of subjects: 28
Study 14746594 — intervention group
Group type: COMPARATOR
Intervention: Standard three-port pars plana vitrectomy without scleral buckling
Number of subjects: 28
Study 11385059 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (250 IU d-alpha tocopherol 3 times daily for 1 year)
Number of subjects: 44
Study 11385059 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by Vitamin E (d-alpha tocopherol for an additional 6 months)
Number of subjects: 44
Study 9265282 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg once daily
Number of subjects: 4159
Study 9265282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4159
Study 8338977 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25-(OH)2D 0.5 microgram/day for 4 weeks
Number of subjects: 10
Study 8338977 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25-(OH)2D 0.5 microgram/day + trichlormethiazide (TZ) 2 mg/day for 4 weeks
Number of subjects: 10
Study 8338977 — intervention group
Group type: COMPARATOR
Intervention: Control (pretreatment)
Number of subjects: 10
Study 8338977 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatment with combined 1,25-(OH)2D and TZ for 11-29 months
Number of subjects: 10
Study 3559779 — intervention group
Group type: COMPARATOR
Intervention: Cardiology textbook chapter on interpreting chest pain
Number of subjects: 82
Study 3559779 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction rule for estimating probability of coronary artery disease
Number of subjects: 82
Study 29980352 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine
Number of subjects: 133
Study 29980352 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine
Number of subjects: 133
Study 26690066 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training/lifestyle intervention (3-month program, mild- to moderate-intensity endurance training, 3-5 times/week, 30-45 min/session, plus strength training, increased salt/water intake)
Number of subjects: 251
Study 26690066 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training/lifestyle intervention
Number of subjects: 251
Study 23584508 — intervention group
Group type: EXPERIMENTAL
Intervention: High hand position
Number of subjects: 80
Study 23584508 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive focus
Number of subjects: 80
Study 23584508 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 80
Study 23584508 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy
Number of subjects: 80
Study 22543739 — intervention group
Group type: EXPERIMENTAL
Intervention: DEH (no fluid replacement)
Number of subjects: 9
Study 22543739 — intervention group
Group type: COMPARATOR
Intervention: HYD (fluid replacement)
Number of subjects: 9
Study 19958308 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 49
Study 19958308 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (40 mg)
Number of subjects: 49
Study 19958308 — intervention group
Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 49
Study 17645559 — intervention group
Group type: EXPERIMENTAL
Intervention: Caiapo (4 g daily for 5 months)
Number of subjects: 27
Study 17645559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 17260200 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate
Number of subjects: 50
Study 17260200 — intervention group
Group type: COMPARATOR
Intervention: Control (no clodronate)
Number of subjects: 50
Study 12471627 — intervention group
Group type: EXPERIMENTAL
Intervention: Papnet
Number of subjects: 108686
Study 12471627 — intervention group
Group type: COMPARATOR
Intervention: Conventional smear
Number of subjects: 108686
Study 10910310 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole sodium, 20 mg once daily
Number of subjects: 268
Study 10910310 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine hydrochloride, 150 mg twice daily
Number of subjects: 268
Study 10910310 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (8 weeks or more)
Number of subjects: 268
Study 10910310 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (8 weeks or more)
Number of subjects: 268
Study 10910310 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 268
Study 9263160 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine (0.3 mg/kg)
Number of subjects: 18
Study 9263160 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine (5 mg/kg)
Number of subjects: 18
Study 9263160 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine (0.3 mg/kg)
Number of subjects: 18
Study 9263160 — intervention group
Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 18
Study 9263160 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 9263160 — intervention group
Group type: EXPERIMENTAL
Intervention: responders
Number of subjects: 18
Study 8501639 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon GV
Number of subjects: 70
Study 8501639 — intervention group
Group type: COMPARATOR
Intervention: Healon
Number of subjects: 70
Study 3307623 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ribavirin treatment
Number of subjects: 25
Study 31296264 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative and stepped structural case management program for depression treatment in nursing home residents.
Number of subjects: 380
Study 27836532 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care plus 20 jumps twice daily
Number of subjects: 41
Study 27836532 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 41
Study 25512099 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (n = 46)
Number of subjects: 93
Study 25512099 — intervention group
Group type: COMPARATOR
Intervention: CNI (n = 47)
Number of subjects: 93
Study 25512099 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (n = 52, subpopulation)
Number of subjects: 93
Study 25512099 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 93
Study 25512099 — intervention group
Group type: COMPARATOR
Intervention: CNI
Number of subjects: 93
Study 23765755 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving training (2 hours after a standard meal)
Number of subjects: 39
Study 21319341 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacerein treatment group (n = 12)
Number of subjects: 26
Study 21319341 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n = 7)
Number of subjects: 26
Study 20015431 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Yunchang Capsule (0.35 g/pill, 2 pills + 1 simulant pill, three times daily)
Number of subjects: 240
Study 20015431 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose Yunchang Capsule (0.35 g/pill, 3 pills, three times daily)
Number of subjects: 240
Study 20015431 — intervention group
Group type: COMPARATOR
Intervention: Control group (Biantong Capsule, 0.35 g/pill, 3 pills, three times daily)
Number of subjects: 240
Study 20015431 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Yunchang Capsule
Number of subjects: 240
Study 20015431 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose Yunchang Capsule
Number of subjects: 240
Study 20015431 — intervention group
Group type: COMPARATOR
Intervention: Control group (Biantong Capsule)
Number of subjects: 240
Study 16428355 — intervention group
Group type: COMPARATOR
Intervention: 1 ml sterile water as placebo (group 1, n = 10)
Number of subjects: 40
Study 16428355 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml 33% sucrose solution (group 2, n = 10)
Number of subjects: 40
Study 16428355 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml sterile water with pacifier (group 3, n = 9)
Number of subjects: 40
Study 16428355 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml 33% sucrose solution with pacifier (group 4, n = 11)
Number of subjects: 40
Study 12893649 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (40 mg daily)
Number of subjects: 3
Study 12893649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 12847731 — intervention group
Group type: EXPERIMENTAL
Intervention: Pollen immunotherapy
Number of subjects: 0
Study 12847731 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐molecular‐weight allergen peptide vaccines
Number of subjects: 0
Study 8855613 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron 4 mg
Number of subjects: 82
Study 8855613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 8855613 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ondansetron and placebo)
Number of subjects: 82
Study 1625259 — intervention group
Group type: EXPERIMENTAL
Intervention: Channel TURP and bilateral orchidectomy
Number of subjects: 22
Study 1625259 — intervention group
Group type: COMPARATOR
Intervention: Bilateral orchidectomy alone
Number of subjects: 22
Study 6487554 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive interactions
Number of subjects: 0
Study 6487554 — intervention group
Group type: COMPARATOR
Intervention: Reflective interactions
Number of subjects: 0
Study 6487554 — intervention group
Group type: COMPARATOR
Intervention: Naive interactions
Number of subjects: 0
Study 30272637 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmet need for transportation
Number of subjects: 417
Study 30272637 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥3 unmet subsistence needs
Number of subjects: 417
Study 29629784 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment group
Number of subjects: 52
Study 29629784 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment group
Number of subjects: 52
Study 26864368 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey RUSF (75 kcal · kg(‐1) · d(‐1) for up to 12 weeks)
Number of subjects: 2230
Study 26864368 — intervention group
Group type: COMPARATOR
Intervention: Soy RUSF (75 kcal · kg(‐1) · d(‐1) for up to 12 weeks)
Number of subjects: 2230
Study 26864368 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey RUSF
Number of subjects: 2230
Study 26864368 — intervention group
Group type: COMPARATOR
Intervention: Soy RUSF
Number of subjects: 2230
Study 24715580 — intervention group
Group type: EXPERIMENTAL
Intervention: TSU-68 plus docetaxel
Number of subjects: 81
Study 24715580 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 81
Study 22337952 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin and fourth generation cardiac troponin T (cTnT)
Number of subjects: 433
Study 22337952 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin and high-sensitivity cardiac troponin T (hs-cTnT)
Number of subjects: 433
Study 22337952 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin
Number of subjects: 433
Study 21118921 — intervention group
Group type: EXPERIMENTAL
Intervention: + mefloquine
Number of subjects: 0
Study 21118921 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic mefloquine
Number of subjects: 0
Study 21118921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17563272 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel loading dose of 300 mg 6-24 hours before intervention and maintenance for 1 month
Number of subjects: 0
Study 17563272 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel treatment continued for at least 24 months
Number of subjects: 0
Study 17563272 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel maintenance only
Number of subjects: 0
Study 17563272 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel treatment after 6 months from bare-metal stenting
Number of subjects: 0
Study 15694077 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceiling lift intervention
Number of subjects: 0
Study 12170167 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroneurography (ENOG)
Number of subjects: 63
Study 12170167 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 63
Study 9707350 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone (Florinef) therapy for orthostatic hypotension
Number of subjects: 41
Study 9707350 — intervention group
Group type: EXPERIMENTAL
Intervention: No fludrocortisone therapy
Number of subjects: 41
Study 9707350 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy elderly persons)
Number of subjects: 41
Study 9707350 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between non-fludrocortisone Parkinson's patients and fludrocortisone Parkinson's patients
Number of subjects: 41
Study 9200279 — intervention group
Group type: EXPERIMENTAL
Intervention: 150‐mg ranitidine effervescent tablets
Number of subjects: 377
Study 9200279 — intervention group
Group type: COMPARATOR
Intervention: 20‐mg famotidine wafers
Number of subjects: 377
Study 2293218 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC-9653 administered alone
Number of subjects: 9
Study 2293218 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC-9653 administered concomitantly with diazepam
Number of subjects: 9
Study 2293218 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC-9653
Number of subjects: 9
Study 2293218 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC-9653 and diazepam administered together
Number of subjects: 9